Detalhe da pesquisa
1.
IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor.
Nat Immunol
; 22(3): 358-369, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33432230
2.
Dynamic peripheral blood immune cell markers for predicting the response of patients with metastatic cancer to immune checkpoint inhibitors.
Cancer Immunol Immunother
; 72(1): 23-37, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35661905
3.
Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients.
Cancer Immunol Immunother
; 72(2): 437-448, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35931835
4.
Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy.
Cancer Immunol Immunother
; 72(2): 385-395, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35907016
5.
The inter-link of ageing, cancer and immunity: findings from real-world retrospective study.
Immun Ageing
; 20(1): 75, 2023 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38102684
6.
Immune-related pneumonitis requiring low-dose prednisone maintenance in one patient with durable complete response.
J Oncol Pharm Pract
; 29(4): 986-991, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36120899
7.
Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma.
Oncologist
; 27(6): e463-e470, 2022 06 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35348754
8.
Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial.
Cancer Immunol Immunother
; 71(8): 1897-1908, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34984540
9.
Quantitative RECIST derived from multiparametric MRI in evaluating response of esophageal squamous cell carcinoma to neoadjuvant therapy.
Eur Radiol
; 32(10): 7295-7306, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36048205
10.
Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature.
BMC Gastroenterol
; 21(1): 399, 2021 Oct 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34688262
11.
Characterization of CD103+ CD8+ tissue-resident T cells in esophageal squamous cell carcinoma: may be tumor reactive and resurrected by anti-PD-1 blockade.
Cancer Immunol Immunother
; 69(8): 1493-1504, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32285170
12.
Exploring a Tumor-Intrinsic PD-L1 Signal with Proximity-Dependent Biotin Identification in Lung Cancer Cells.
Biochemistry
; 58(18): 2293-2296, 2019 05 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31021072
13.
S-15 in combination of Akt inhibitor promotes the expansion of CD45RA-CCR7+ tumor infiltrating lymphocytes with high cytotoxic potential and downregulating PD-1+Tim-3+ cells as well as regulatory T cells.
Cancer Cell Int
; 19: 322, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31827396
14.
Linc00210 drives Wnt/ß-catenin signaling activation and liver tumor progression through CTNNBIP1-dependent manner.
Mol Cancer
; 17(1): 73, 2018 03 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29540185
15.
TGFß1-induced down-regulation of microRNA-138 contributes to epithelial-mesenchymal transition in primary lung cancer cells.
Biochem Biophys Res Commun
; 496(4): 1169-1175, 2018 02 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29407170
16.
Retraction Note to: Linc00210 drives Wnt/ß-catenin signaling activation and liver tumor progression through CTNNBIP1-dependent manner.
Mol Cancer
; 21(1): 161, 2022 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35945589
17.
Tumor-infiltrating CD4+ T cells in patients with gastric cancer.
Cancer Cell Int
; 17: 114, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29213216
18.
Knockdown of NDRG1 promote epithelial-mesenchymal transition of colorectal cancer via NF-κB signaling.
J Surg Oncol
; 114(4): 520-7, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27338835
19.
Pretreatment CD8+PD-1+ to CD4+PD-1+ ratio is associated with the prognosis of advanced melanoma patients treated with PD-1 inhibitors.
Melanoma Res
; 2024 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38647119
20.
Subclone from CT26 resistant to anti-PD-1 therapy associated with increased expression of genes related to glucocorticoids.
Transl Oncol
; 46: 102031, 2024 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38861853